尽管基因编辑领域形势艰难，但一家公司却引起了一些关注并获得了资金。总部位于剑桥的 Arbor 生物技术公司已经获得了 7350 万美元的 C 轮融资，用于推进其基于 CRISPR 的基因治疗产品线，目标是肝脏和中枢神经系统。

Arbor Biotechnologies是一家治疗性基因药物技术研发商，旨在提供人类诊断开发服务。从患者开始，努力了解疾病的基本遗传病理学。通过基于CRISPR的基因组编辑器的大型工具箱，定制治疗疾病的方法，其平台采用了多种技术和技巧，包括人工智能、基因组测序、基因合成和高通量筛选，使药物开发商能够加快发现用于改善人类健康和可持续性的蛋白质。近日，Arbor Biotechnologies宣布完 ...

The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...

At a time when CRISPR companies have struggled, the Feng Zhang spinoff Arbor Biotechnologies gets a cash infusion to head to clinical trials.

The arbor is traditionally used to define a pathway ... Bore countersink holes if needed. Cut the 2x12 arch material to ...